Biodexa Pharmaceuticals Plc - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
BDRX Nasdaq 2836 www.biodexapharma.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Biodexa Pharmaceuticals Plc

Biodexa Receives Orphan Drug Designation in Europe for eRapa in FAP - May 12th, 2025 12:30 pm
Result of General Meeting - May 2nd, 2025 8:30 pm
Notice of General Meeting - Apr 17th, 2025 12:30 pm
Preliminary Results for the Year Ended 31 December 2024 - Apr 11th, 2025 12:30 pm
With Fast Track Designation in Hand, a Successful Protocol Discussion with FDA, and CROs in Place, Biodexa is on Track to Initiate its Funded Phase 3 Trial in FAP Next Quarter - Mar 19th, 2025 11:00 am
Biodexa Announces Successful Outcome of a Type C Meeting with FDA Regarding the Phase 3 Program for eRapa in FAP - Mar 10th, 2025 12:30 pm
Biodexa Announces Appointment of Precision for Medicine LLC as CRO for European Component of Phase 3 Study of eRapa in FAP - Mar 6th, 2025 1:30 pm
Biodexa Announces Allowance of U.S. Patent Covering Oral Rapamycin Nanoparticle Preparations (“eRapa”) and Use - Feb 24th, 2025 1:30 pm
Presenting on the Emerging Growth Conference 79 Day 2 on February 19 Register Now - Feb 19th, 2025 11:00 am
Biodexa Pharmaceuticals PLC to Present at the Emerging Growth Conference on February 19, 2025 - Feb 13th, 2025 1:30 pm
Following Positive Phase 2 Results and Orphan Drug Designation, Biodexa's FAP Drug Receives FDA Fast Track Status - Feb 12th, 2025 12:30 pm
Biodexa Receives US FDA Fast Track Designation for eRapa in Familial Adenomatous Polyposis - Feb 10th, 2025 1:30 pm
Biodexa Strengthens Management Team - Appointment of Dr Gary A. Shangold as Chief Medical Officer - Jan 22nd, 2025 1:30 pm
Gaining Momentum, Biodexa is Advancing Two Recent Acquisitions Through the Clinic - Nov 21st, 2024 12:35 pm
Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Regains Compliance For Continued Listing on Nasdaq - Nov 12th, 2024 1:48 pm
Biodexa's MX-110 Continues to Show Promise in Recurrent Glioblastoma (rGBM), the Deadliest Brain Cancer - Oct 17th, 2024 11:30 am
Biodexa Announces Successful Appeal of Nasdaq Delisting - Oct 15th, 2024 8:15 pm
Biodexa Provides Update on Progression Free and Overall Survival in Phase 1 Study of MTX110 in Recurrent Glioblastoma - Oct 4th, 2024 12:30 pm
Interim results for the six months ended June 30, 2024 - Sep 26th, 2024 12:30 pm
ADR Ratio Change - Sep 19th, 2024 8:30 pm